Navigation Links
ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
Date:11/12/2008

lso reported visiting an average of 4.4 different physicians before receiving an accurate diagnosis of HAE. In addition, survey participants had an average of two immediate and two extended family members that had been diagnosed with HAE, but only 48 percent of their immediate family members and 26 percent of their extended family members had been tested for HAE.

"Accurate, timely diagnosis of HAE patients continues to be a challenge, and despite the fact that HAE is a hereditary disorder, testing family members is not common practice; a consensus statement may lead to improved and earlier diagnosis of patients with HAE," said Timothy Craig, DO, professor of medicine, Penn State University, who co-presented the survey data. "These findings indicate that testing family members for HAE should be a primary concern for those caring for patients with the disorder, and patients should be alerted to the need for screening of their family members."

About Cinryze C1 Inhibitor (human)

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 inhibitor product that has been approved by FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. C1 inhibitor therapy has been used acutely for more than 30 years in Europe to treat patients with C1 inhibitor deficiency. Cinryze has not been approved for acute treatment in the United States or any other jurisdiction.

Cinryze has been well tolerated. The most common adverse reactions observed have been upper respiratory infection, sinusitis, rash and headache. No drug-related serious adverse events (SAEs) have been observed in clinical trials. Severe hypersensitivity reactions may occur. Thrombotic events have occurred in patients receiving high dose off-label C1 inhibitor therapy well above the approved treatment dosage regimen. With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, the
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
2. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
3. ViroPharma Announces Discontinuation of HCV-796 Development
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. ViroPharma to Present at the Natixis Bleichroeder Conference
7. ViroPharma to Present at Three Upcoming Healthcare Conferences
8. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
9. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
10. Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
11. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... ALBANY, New York , July 11, 2014 /PRNewswire/ ... published by Transparency Market Research "Endoscopy Devices Market (Endoscopes, ... Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019" the ... billion in 2012 and is expected to grow at ... reach an estimated value of USD 36.9 billion in ...
(Date:7/11/2014)... , July 11, 2014 ... to Safety & Health Expo 2014 were ... move to London , ... attending exhibition.          ... http://photos.prnewswire.com/prnh/20140711/696892-a )      (Photo: ...
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
(Date:7/11/2014)... 11, 2014 Operators and ... billion in fuel costs now that model ... current GHG standards are phasing in ... upon themselves to install new features into ... reduction technologies , 2.    Efficient driveline components which ...
(Date:7/11/2014)... July 11, 2014 Ticket Down is ... Concord Pavilion . When it comes to the summer concert ... The 37-year-old Georgia native is one of the biggest names in ... business. Bryan is currently out on his “That’s My Kind of ... stops the tour will be making through the rest of the ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Global enterprises ... services to outsource day-to-day management activities. Managed services offer ... additional expenses. The economic slowdown resulted into rising operational ... and expenses is considered to be the global market ... future. , The global managed services market is estimated ...
(Date:7/11/2014)... The Miriam Hospital have found that people with ... rates of smoking than those without mobility impairments. ... to attempt quitting than those without mobility impairments, ... for this population. The study and its findings ... the American Journal of Public Health . ...
(Date:7/11/2014)... 2014 (HealthDay News) -- Delaying surgery to repair damage to ... the middle of the knee -- could increase a young ... the medical records of 130 patients, aged 8 to 16, ... surgery less than six weeks after their injury, 37 had ... surgery more than three months after their injury. The ...
Breaking Medicine News(10 mins):Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Miriam Hospital study examines smoking prevalence 2Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2
... ... tests green product performance on real-world soils. , ... Lowell, MA (PRWEB) April 22, 2010 -- The ... Massachusetts Lowell (UMass Lowell) TURI Lab as a High Performance Cleaning Product (HPCP) under ...
... The New Mexico ... ... Tamaya Mist Spa & Salon at the Hyatt Regency Tamaya Resort & Spa has recently ... the nation,s leading travel magazines. The New Mexico spa resort was ranked as the ...
... Major ... cannabis , ... April 22, 2010 -- MarijuanaDoctors.com, the nation’s leading online medical marijuana evaluations company, and ... forces to help patients across the country find quality medical marijuana doctors ...
... ... coverage – just the beginning. , ... Waterloo, IA (Vocus) April 21, 2010 -- VGM ... including: Home Medical Equipment, Durable Medical Equipment, Orthotic, Prosthetic, Medical Device Manufacturers, Medical ...
... According to a study conducted at Thomas Jefferson ... a cost-effective alternative to invasive cardiac catheterization in the ... but a less than 50 percent chance of actually ... will be published in the May issue of the ...
... before the Medicare Evidence Development and Coverage Advisory ... treatment of localized prostate cancer. MEDCAC provides advice ... Medicaid Services for what is covered by Medicare ... focused on the risks, benefits and outcomes of ...
Cached Medicine News:Health News:IEHA and UMass Lowell Recognize Activeion as a High Performance Cleaning Product 2Health News:IEHA and UMass Lowell Recognize Activeion as a High Performance Cleaning Product 3Health News:Leading New Mexico Resort Spa At Hyatt Regency Tamaya Ranked Among The Country's Best By Conde Nast Traveler 2Health News:Leading New Mexico Resort Spa At Hyatt Regency Tamaya Ranked Among The Country's Best By Conde Nast Traveler 3Health News:MarijuanaDoctors.com and PotLocator.com Form Alliance, Expand Medical Marijuana iPhone App 2Health News:MarijuanaDoctors.com and PotLocator.com Form Alliance, Expand Medical Marijuana iPhone App 3Health News:Coronary CTA a cost-effective alternative to cardiac catheterization for the evaluation of CAD 2
... offers the comfort of a surgical microscope ... The microscope offers brilliant resolution, large depth ... color reproduction. A separate prism for optimum ... with a special jalousie diaphragm. It offers ...
... surgical magnifying loupes are quality surgical ... which provide the healthcare professional a ... depth of field. Each set of ... fully lined wooden box and includes ...
... field-of-view enables high-quality full-coverage body imaging. New ... architecture. New powerful Quasar Dual gradients designed ... to 80 mT/m SR 200. New ... exploit the power of 3.0T in a ...
GE's Signa Contour/i system uses the latest innovations from around the world to bring new standards in quality and value to MRI....
Medicine Products: